STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in China
Big drugmakers tell U.S. House committee they will halt clinical trials at some hospitals in China.
STAT PlusPharmalot Big drugmakers tell House committee they will halt clinical trials at some hospitals in China Committee has concerns about intellectual property, ethical standards Manage alerts for this article Save this story for later Share this article By Ed SilvermanNov. 19, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.
A few of the largest pharmaceutical companies have told a Congressional committee that they do not plan to start new clinical trial sites in the Xinjiang region of China or at hospitals affiliated with the Chinese military. The disclosure was made by the House Select Committee on China, which last June opened investigations into five companies — Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb — over concerns about intellectual property exposure, military entanglements, and ethical standards at trial sites in sensitive regions of the country.Advertisement All five companies indicated they would not initiate new clinical studies at sites linked to the People’s Liberation Army, which is the military wing of the Chinese Communist Party. In letters sent to the drugmakers, the House committee noted rising concern over the possibility of security risks.
STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account?
Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.
Subscribe Log In biotechnology, China, drug development, Pharmaceuticals, Policy, public health, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. STAT+ Newsletter Pharmalot columnist Ed Silverman rounds up the most important news of the day in the global drug industry Recommended Pharmalot November 19, 2026 STAT Plus: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more Pharmalot November 18, 2026 STAT Plus: NIH to move last group of its research chimps to a sanctuary Advertisement Pharmalot November 18, 2026 STAT Plus: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more Pharmalot November 17, 2026 STAT Plus: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more Pharmalot November 16, 2026 STAT Plus: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns Subscriber Picks
comments(0)
5-min edit window · permanent after that